<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04944706</url>
  </required_header>
  <id_info>
    <org_study_id>TSL-TCM-QSYQDW-HFpEF-Ⅱ</org_study_id>
    <nct_id>NCT04944706</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction</brief_title>
  <official_title>Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction: a Randomized, Double-blind, Basic-treatment-loading, Placebo-controlled, Multicenter Phase Ⅱ Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tasly Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tasly Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main objective: To evaluate the efficacy, safety and clinical dose exploration of Qishen Yiqi&#xD;
      dripping pills in the treatment of chronic heart failure with preserved ejection fraction.&#xD;
&#xD;
      Exploratory research objective: To explore the changes of endogenous substances in vivo&#xD;
      before and after drug administration, to interpret the mechanism of drug action through&#xD;
      metabolomics and systems biology methods, and to find potential clinical biomarkers for&#xD;
      exploratory subgroup analysis of clinical trials.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6-Minutes-Walking-Test (6MWT)</measure>
    <time_frame>Baseline to weeks 12 and 24</time_frame>
    <description>Change from baseline to weeks 12 and 24 in exercise capacity as measured by the 6-Minutes-Walking-Test (6MWT) distance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>Baseline to weeks 2,4,8,12,16,20 and 24</time_frame>
    <description>Change from baseline to weeks 2,4,8,12,16,20 and 24 in NT-proBNP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LAVI, E/ E ', E 'mean value, LVEF and tricuspid regurgitation velocity</measure>
    <time_frame>Baseline to weeks 4,12 and 24</time_frame>
    <description>Change from baseline to weeks 4,12 and 24 in left atrial volume index, mitral inflow velocity early diastolic blood flow velocity peak to mitral annular relaxation velocity ratio, mitral annular relaxation velocity mean value, left ventricular ejection fraction and tricuspid regurgitation velocity measured by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations for heart failure (first or repeated) and deaths from cardiovascular disease</measure>
    <time_frame>Week 24</time_frame>
    <description>Compound and separate rates of hospitalization for heart failure (first or repeated) and death from cardiovascular disease at week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA classification</measure>
    <time_frame>Baseline to weeks 2,4,8,12,16,20 and 24</time_frame>
    <description>Percentage of subjects whose NYHA classification improved/worsened/remained unchanged from baseline to weeks 2,4,8,12,16,20 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minnesota Living With Heart Failure Questionnaire(MLHFQ) Score</measure>
    <time_frame>Baseline to weeks 12 and 24</time_frame>
    <description>Change from baseline to weeks 12 and 24 in Minnesota Living With Heart Failure Questionnaire(MLHFQ) Score.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Chronic Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The standard basic treatment is given according to the guidelines related to the underlying disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The standard basic treatment is given according to the guidelines related to the underlying disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The standard basic treatment is given according to the guidelines related to the underlying disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qishen Yiqi dripping pills 2 bags/time + Qishen Yiqi dripping pills placebo 2 bags/time</intervention_name>
    <description>Take 3 times a day after meals,24 weeks</description>
    <arm_group_label>Low dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qishen Yiqi dripping pills 4 bags/time</intervention_name>
    <description>Take 3 times a day after meals,24 weeks</description>
    <arm_group_label>High dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qishen Yiqi dripping pills placebo 4 bags/time</intervention_name>
    <description>Take 3 times a day after meals,24 weeks</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects aged ≥ 18 years and ≤75 years&#xD;
&#xD;
          -  Diagnosed as chronic heart failure with preserved ejection fraction according to the&#xD;
             Guidelines for Diagnosis and Treatment of Heart Failure in China 2018&#xD;
&#xD;
               1. Have symptoms and/or signs of chronic heart failure at least 30 days before the&#xD;
                  trial&#xD;
&#xD;
               2. LVEF≥50% according to echocardiography during screening stage&#xD;
&#xD;
               3. BNP &gt; 130 ng/L and/or NT-proBNP &gt; 400 ng/L&#xD;
&#xD;
               4. Cardiac structural changes according to echocardiography during screening stage,&#xD;
                  in line with at least one of the following:&#xD;
&#xD;
                    1. : LAVI&gt;34ml/m2&#xD;
&#xD;
                    2. : E/e'≥13, average e'(interventricular septum and free wall)&lt;9cm/s&#xD;
&#xD;
          -  NYHAⅡ-Ⅲ&#xD;
&#xD;
          -  Patients with hypertension received a stable dose of antihypertensive therapy for at&#xD;
             least 4 weeks and kept their blood pressure at an ideal level for at least 2 months&#xD;
&#xD;
          -  Ability to understand the requirements of the study and willingness to provide written&#xD;
             informed consent&#xD;
&#xD;
          -  Have no pregnancy program and take effective contraceptive measures voluntarily&#xD;
&#xD;
          -  Abide by the experimental protocol and cooperate with the data collection according to&#xD;
             the researcher's judgment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  People with any of the following cardiovascular diseases:&#xD;
&#xD;
               1. Patients with acute decompensated heart failure who need to use quick-acting&#xD;
                  diuretics, vasodilators, or positive inotropic drugs for treatment, or in the&#xD;
                  adjustment period of acute decompensated heart failure treatment, and the&#xD;
                  adjustment time is less than 1 month&#xD;
&#xD;
               2. Clinical evidence of acute coronary syndrome (including myocardial infarction,&#xD;
                  unstable angina pectoris), or prior revascularization (such as PCI, CABG), or&#xD;
                  implantable device (such as ICD, CRT), or other cardiac/cardiovascular procedures&#xD;
                  within 6 months before screening stage&#xD;
&#xD;
               3. Implantable devices (e.g. ICD, CRT), revascularization (e.g. PCI, CABG), or other&#xD;
                  cardiac/cardiovascular procedures are expected to be performed during the trial&#xD;
                  period&#xD;
&#xD;
               4. Patients with acute myocarditis, invasive cardiomyopathy, constrictive&#xD;
                  pericarditis, cardiac tamponade, hypertrophic obstructive cardiomyopathy, cardiac&#xD;
                  shock, hemodynamic abnormalities of heart valve disease significantly narrow&#xD;
                  and/or regurgitation (moderate or above, etc.), Ⅱ degrees above Ⅱ type&#xD;
                  atrioventricular block placement pacemaker therapy, average QTc &gt; 450 ms or heart&#xD;
                  rate &lt; 50 times/min&#xD;
&#xD;
               5. Patients with pulmonary artery embolism caused by pulmonary hypertension, chronic&#xD;
                  obstructive pulmonary disease and other serious pulmonary diseases&#xD;
&#xD;
               6. Hypertension that is difficult to control with medication (systolic blood&#xD;
                  pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg)&#xD;
&#xD;
               7. Symptomatic hypotension and/or systolic blood pressure &lt;100 mmHg&#xD;
&#xD;
          -  Severe renal insufficiency: eGFR &lt; 30 ml/min/1.73m2&#xD;
&#xD;
          -  ALT and AST &gt; 3 times upper the limit of normal values in local laboratories, and/or&#xD;
             total bilirubin &gt; 1.5 times upper the limit of normal values in local laboratories&#xD;
&#xD;
          -  Serum potassium ≥5.5 mmol/L&#xD;
&#xD;
          -  HbA1c≥9.0%, or fasting blood glucose &gt;13.9 mmol/L&#xD;
&#xD;
          -  Diabetic patients who are using sodium-glucose cotransporter 2 inhibitors and cannot&#xD;
             stop using them during the trial, such as dagliredin, entagliredin, and cagliredin&#xD;
&#xD;
          -  The ECG examination indicated the onset of atrial fibrillation during the screening&#xD;
             period or previous history of atrial fibrillation&#xD;
&#xD;
          -  Hemoglobin &lt; 9.0 g/dL&#xD;
&#xD;
          -  Patients have stroke 3 months before the screening period&#xD;
&#xD;
          -  Concomitant mental illness and poor condition control, which affects the signing of&#xD;
             informed consent or presentation of adverse events&#xD;
&#xD;
          -  Patients with active malignancies (including those currently under oncology treatment)&#xD;
&#xD;
          -  Unable to conduct the 6-minute walking distance test due to physical impairment or&#xD;
             other non-cardiac reasons&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
&#xD;
          -  Allergic constitution, or allergic to the test drug or its ingredients&#xD;
&#xD;
          -  Participate in clinical trials of other drugs within 3 months before screening&#xD;
&#xD;
          -  The researchers did not consider it appropriate to participate in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rui Liu</last_name>
    <phone>022-86343626</phone>
    <email>liurui2@tasly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Bengbu Medical College</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ningru Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fang Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhicheng Jing</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Bejing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suxin Luo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hebei General Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rongpin Du</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Xinxiang Medical College</name>
      <address>
        <city>Xinxiang</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guotian Yin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weihong Jiang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xinli Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liqun Ren</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Japan Union Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ping Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huanzhen Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital Of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guoen Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Chest Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongliang Cong</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

